Primary Series Hospitalization/Severe Disease ■ non-mRNA ■ Multiple mRNA Country VE (95% CI) Study Design С H Bar-On et al., 2021 Israel 0.95 (0.92, 0.97) 0.93 (0.88, 0.97) MC Barda et al., 2021 Israel \vdash С Muhsen et al., 2022 0.93 (0.85, 0.97) Israel $\overline{}$ Sharma et al., 2021 USA MC0.45 (0.27, 0.58) С Mattiuzzi and Lippi, 2022 Italy 0.69 (0.56, 0.78) McConeghy et al., 2022 (S1) С 0.82 (0.56, 0.94) USA С McConeghy et al., 2022 (S2) USA 0.46 (-0.16, 0.79) Mehta et al., 2022 USA MC0.81 (0.80, 0.82) С Tartof et al., 2022 USA 0.70 (0.48, 0.83) Butt et al, 2022 USA MC0.52 (0.46, 0.57) Hulme et al., 2022 UK MC0.80 (0.78, 0.82) Andersson et al., 2022 Finland MC \vdash 0.96 (0.88, 1.00) Andersson et al., 2022 MC0.88 (0.71, 1.00) Norway 0.90 (0.80, 1.00) Andersson et al., 2022 Sweden MC Andersson et al., 2022 Sweden MC0.88 (0.81, 0.95) Ioannou et al., 2022 USA MC $\qquad \qquad \blacksquare \qquad \qquad \blacksquare$ 0.53 (0.48, 0.58) С Ng et al., 2022 Singapore 0.70 (0.49, 0.82) Portugal С 0.21 (0.02, 0.36) Kislaya et al., 2022 (60-79yo) С Portugal 0.16 (0.01, 0.28) Kislaya et al., 2022 (80+yo) Ridgway et al., 2022 USA MCC $\quad \rule{0mm}{3mm} \quad {0mm}{3mm} \quad \rule{0mm}{3mm} \quad {0mm}{3mm} \quad {0mm}{3mm}{3mm} \quad {0mm}{3mm} \quad {$ 0.59 (0.54, 0.63) USA MCDesai et al., 2022 0.44 (0.02, 0.68) Chemaitelly et al., 2022 Qatar MC 0.80 (0.56, 0.91) 0.25 -0.250 0.5 0.75 1 Vaccine Effectiveness (VE)

Mortality

Study	Country	Design	VE (95% CI)
Barda et al., 2021	Israel	MC	0.81 (0.59, 0.97)
Arbel et al., 2021	Israel	С	0.90 (0.86, 0.93)
Muhsen et al., 2022	Israel	С	0.96 (0.84, 0.99)
Mattiuzzi and Lippi, 2022	Italy	С	0.97 (0.56, 1.00)
Hulme et al., 2022	UK	MC	0.88 (0.85, 0.91)
Silva-Valencia et al., 2022	Peru	MCC	0.87 (0.84, 0.90)
loannou et al., 2022	USA	MC	0.79 (0.71, 0.85)
Kislaya et al., 2022 (60-79yo)	Portugal	С	0.14 (-0.05, 0.30)
Kislaya et al., 2022 (80+yo)	Portugal	С	0.13 (0.01, 0.24)
			-0.25 0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)